Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts

Koichi Morisaki, Rei Shibata, Noriko Takahashi, Noriyuki Ouchi, Yoshihiko Maehara, Toyoaki Murohara, Kimihiro Komori

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Intimal hyperplasia is a major obstacle to patency after vein grafting. Several clinical trials revealed that pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, exerts beneficial actions on cardiovascular complications. We investigated whether pioglitazone modulates intimal hyperplasia in experimental rabbit autologous vein grafts. Methods: Male Japanese White rabbits were randomly divided into two groups: one group received pioglitazone as food admixture at a concentration of 0.01%, and the other did not (control). One week later, each group underwent reversed autologous vein bypass grafting of the right common carotid artery using ipsilateral external jugular vein. Pioglitazone therapy was continued after surgery and until harvest. Intimal hyperplasia of the grafted vein was assessed at 28 days. Two weeks after implantation, proliferative cells in the neointima were identified by immunohistochemical staining with Ki-67 monoclonal antibody. To determine apoptotic cells, we performed terminal deoxynucleotidyl transferase-mediated deoxyuride-5′-triphosphate nick-end labeling (TUNEL) staining. Blood samples were collected at 28 days after implantation for measuring metabolic parameters such as plasma glucose and total cholesterol. Adiponectin levels were determined by Western blot analysis. Finally, we assessed adiponectin-related signaling pathway, 5′ adenosine monophosphate-activated protein kinase (AMPK), and extracellular signal-regulated kinase (ERK) in the grafted vein by Western blot analysis. Results: Treatment with pioglitazone markedly inhibited intimal hyperplasia of carotid interposition-reversed jugular vein grafts in the pioglitazone group (0.54 ± 0.04 mm 2) vs control (0.93 ± 0.04 mm 2; n = 7; P <.01). Pioglitazone treatment reduced the number of Ki-67-positive proliferating cells in the neointima of the vein grafts at 14 days after implantation in the pioglitazone group (4.1% ± 1.1%) vs the controls (16.8% ± 1.7%; P <.05). The frequency of TUNEL-positive apoptotic cells was enhanced by pioglitazone (3.5% ± 0.5%) vs the controls (1.2% ± 0.1%; P <.05). Pioglitazone treatment also increased plasma levels of adiponectin, a vascular protective hormone, and led to an increase in phosphorylation of AMPK and a decrease in phosphorylation of ERK in the grafted vein. Conclusions: Pioglitazone attenuates intimal hyperplasia of the vein graft after autologous bypass grafting by its ability to suppress cell proliferation and enhance apoptosis. Pioglitazone could represent a therapeutic target for the prevention of graft failure after bypass grafting.

Original languageEnglish
Pages (from-to)1753-1759
Number of pages7
JournalJournal of Vascular Surgery
Volume54
Issue number6
DOIs
Publication statusPublished - Dec 1 2011

Fingerprint

pioglitazone
Tunica Intima
Hyperplasia
Veins
Rabbits
Transplants
Adiponectin
Neointima
Extracellular Signal-Regulated MAP Kinases
Jugular Veins
Adenosine Monophosphate
Protein Kinases
Western Blotting
Phosphorylation
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Morisaki, K., Shibata, R., Takahashi, N., Ouchi, N., Maehara, Y., Murohara, T., & Komori, K. (2011). Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts. Journal of Vascular Surgery, 54(6), 1753-1759. https://doi.org/10.1016/j.jvs.2011.06.081

Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts. / Morisaki, Koichi; Shibata, Rei; Takahashi, Noriko; Ouchi, Noriyuki; Maehara, Yoshihiko; Murohara, Toyoaki; Komori, Kimihiro.

In: Journal of Vascular Surgery, Vol. 54, No. 6, 01.12.2011, p. 1753-1759.

Research output: Contribution to journalArticle

Morisaki, K, Shibata, R, Takahashi, N, Ouchi, N, Maehara, Y, Murohara, T & Komori, K 2011, 'Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts', Journal of Vascular Surgery, vol. 54, no. 6, pp. 1753-1759. https://doi.org/10.1016/j.jvs.2011.06.081
Morisaki, Koichi ; Shibata, Rei ; Takahashi, Noriko ; Ouchi, Noriyuki ; Maehara, Yoshihiko ; Murohara, Toyoaki ; Komori, Kimihiro. / Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts. In: Journal of Vascular Surgery. 2011 ; Vol. 54, No. 6. pp. 1753-1759.
@article{f51ae50430b64077891c03c9c3b0015a,
title = "Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts",
abstract = "Background: Intimal hyperplasia is a major obstacle to patency after vein grafting. Several clinical trials revealed that pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, exerts beneficial actions on cardiovascular complications. We investigated whether pioglitazone modulates intimal hyperplasia in experimental rabbit autologous vein grafts. Methods: Male Japanese White rabbits were randomly divided into two groups: one group received pioglitazone as food admixture at a concentration of 0.01{\%}, and the other did not (control). One week later, each group underwent reversed autologous vein bypass grafting of the right common carotid artery using ipsilateral external jugular vein. Pioglitazone therapy was continued after surgery and until harvest. Intimal hyperplasia of the grafted vein was assessed at 28 days. Two weeks after implantation, proliferative cells in the neointima were identified by immunohistochemical staining with Ki-67 monoclonal antibody. To determine apoptotic cells, we performed terminal deoxynucleotidyl transferase-mediated deoxyuride-5′-triphosphate nick-end labeling (TUNEL) staining. Blood samples were collected at 28 days after implantation for measuring metabolic parameters such as plasma glucose and total cholesterol. Adiponectin levels were determined by Western blot analysis. Finally, we assessed adiponectin-related signaling pathway, 5′ adenosine monophosphate-activated protein kinase (AMPK), and extracellular signal-regulated kinase (ERK) in the grafted vein by Western blot analysis. Results: Treatment with pioglitazone markedly inhibited intimal hyperplasia of carotid interposition-reversed jugular vein grafts in the pioglitazone group (0.54 ± 0.04 mm 2) vs control (0.93 ± 0.04 mm 2; n = 7; P <.01). Pioglitazone treatment reduced the number of Ki-67-positive proliferating cells in the neointima of the vein grafts at 14 days after implantation in the pioglitazone group (4.1{\%} ± 1.1{\%}) vs the controls (16.8{\%} ± 1.7{\%}; P <.05). The frequency of TUNEL-positive apoptotic cells was enhanced by pioglitazone (3.5{\%} ± 0.5{\%}) vs the controls (1.2{\%} ± 0.1{\%}; P <.05). Pioglitazone treatment also increased plasma levels of adiponectin, a vascular protective hormone, and led to an increase in phosphorylation of AMPK and a decrease in phosphorylation of ERK in the grafted vein. Conclusions: Pioglitazone attenuates intimal hyperplasia of the vein graft after autologous bypass grafting by its ability to suppress cell proliferation and enhance apoptosis. Pioglitazone could represent a therapeutic target for the prevention of graft failure after bypass grafting.",
author = "Koichi Morisaki and Rei Shibata and Noriko Takahashi and Noriyuki Ouchi and Yoshihiko Maehara and Toyoaki Murohara and Kimihiro Komori",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.jvs.2011.06.081",
language = "English",
volume = "54",
pages = "1753--1759",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts

AU - Morisaki, Koichi

AU - Shibata, Rei

AU - Takahashi, Noriko

AU - Ouchi, Noriyuki

AU - Maehara, Yoshihiko

AU - Murohara, Toyoaki

AU - Komori, Kimihiro

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background: Intimal hyperplasia is a major obstacle to patency after vein grafting. Several clinical trials revealed that pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, exerts beneficial actions on cardiovascular complications. We investigated whether pioglitazone modulates intimal hyperplasia in experimental rabbit autologous vein grafts. Methods: Male Japanese White rabbits were randomly divided into two groups: one group received pioglitazone as food admixture at a concentration of 0.01%, and the other did not (control). One week later, each group underwent reversed autologous vein bypass grafting of the right common carotid artery using ipsilateral external jugular vein. Pioglitazone therapy was continued after surgery and until harvest. Intimal hyperplasia of the grafted vein was assessed at 28 days. Two weeks after implantation, proliferative cells in the neointima were identified by immunohistochemical staining with Ki-67 monoclonal antibody. To determine apoptotic cells, we performed terminal deoxynucleotidyl transferase-mediated deoxyuride-5′-triphosphate nick-end labeling (TUNEL) staining. Blood samples were collected at 28 days after implantation for measuring metabolic parameters such as plasma glucose and total cholesterol. Adiponectin levels were determined by Western blot analysis. Finally, we assessed adiponectin-related signaling pathway, 5′ adenosine monophosphate-activated protein kinase (AMPK), and extracellular signal-regulated kinase (ERK) in the grafted vein by Western blot analysis. Results: Treatment with pioglitazone markedly inhibited intimal hyperplasia of carotid interposition-reversed jugular vein grafts in the pioglitazone group (0.54 ± 0.04 mm 2) vs control (0.93 ± 0.04 mm 2; n = 7; P <.01). Pioglitazone treatment reduced the number of Ki-67-positive proliferating cells in the neointima of the vein grafts at 14 days after implantation in the pioglitazone group (4.1% ± 1.1%) vs the controls (16.8% ± 1.7%; P <.05). The frequency of TUNEL-positive apoptotic cells was enhanced by pioglitazone (3.5% ± 0.5%) vs the controls (1.2% ± 0.1%; P <.05). Pioglitazone treatment also increased plasma levels of adiponectin, a vascular protective hormone, and led to an increase in phosphorylation of AMPK and a decrease in phosphorylation of ERK in the grafted vein. Conclusions: Pioglitazone attenuates intimal hyperplasia of the vein graft after autologous bypass grafting by its ability to suppress cell proliferation and enhance apoptosis. Pioglitazone could represent a therapeutic target for the prevention of graft failure after bypass grafting.

AB - Background: Intimal hyperplasia is a major obstacle to patency after vein grafting. Several clinical trials revealed that pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, exerts beneficial actions on cardiovascular complications. We investigated whether pioglitazone modulates intimal hyperplasia in experimental rabbit autologous vein grafts. Methods: Male Japanese White rabbits were randomly divided into two groups: one group received pioglitazone as food admixture at a concentration of 0.01%, and the other did not (control). One week later, each group underwent reversed autologous vein bypass grafting of the right common carotid artery using ipsilateral external jugular vein. Pioglitazone therapy was continued after surgery and until harvest. Intimal hyperplasia of the grafted vein was assessed at 28 days. Two weeks after implantation, proliferative cells in the neointima were identified by immunohistochemical staining with Ki-67 monoclonal antibody. To determine apoptotic cells, we performed terminal deoxynucleotidyl transferase-mediated deoxyuride-5′-triphosphate nick-end labeling (TUNEL) staining. Blood samples were collected at 28 days after implantation for measuring metabolic parameters such as plasma glucose and total cholesterol. Adiponectin levels were determined by Western blot analysis. Finally, we assessed adiponectin-related signaling pathway, 5′ adenosine monophosphate-activated protein kinase (AMPK), and extracellular signal-regulated kinase (ERK) in the grafted vein by Western blot analysis. Results: Treatment with pioglitazone markedly inhibited intimal hyperplasia of carotid interposition-reversed jugular vein grafts in the pioglitazone group (0.54 ± 0.04 mm 2) vs control (0.93 ± 0.04 mm 2; n = 7; P <.01). Pioglitazone treatment reduced the number of Ki-67-positive proliferating cells in the neointima of the vein grafts at 14 days after implantation in the pioglitazone group (4.1% ± 1.1%) vs the controls (16.8% ± 1.7%; P <.05). The frequency of TUNEL-positive apoptotic cells was enhanced by pioglitazone (3.5% ± 0.5%) vs the controls (1.2% ± 0.1%; P <.05). Pioglitazone treatment also increased plasma levels of adiponectin, a vascular protective hormone, and led to an increase in phosphorylation of AMPK and a decrease in phosphorylation of ERK in the grafted vein. Conclusions: Pioglitazone attenuates intimal hyperplasia of the vein graft after autologous bypass grafting by its ability to suppress cell proliferation and enhance apoptosis. Pioglitazone could represent a therapeutic target for the prevention of graft failure after bypass grafting.

UR - http://www.scopus.com/inward/record.url?scp=82955187046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955187046&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2011.06.081

DO - 10.1016/j.jvs.2011.06.081

M3 - Article

VL - 54

SP - 1753

EP - 1759

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 6

ER -